New drugs for tumors, new drugs for tuberculosis, new coronavirus vaccines... New pharmaceutical products at the service trade fair

(Health Times reporter Xu Tingting Tan Qixin) 16 new anti-tumor drugs, all of which have been commercialized; In recent years, the only class 1 innovative drug approved in the cardiovascular field has been included in medical insurance; Recombinant novel coronavirus protein vaccines have protected 100 million people.

BeiGene: 16 new anti-tumor drugs, all of which have been commercialized

"What we are showing this time is 16 anti-tumor drugs that have been commercialized, including 3 independently developed products and 13 authorized introduction products, all of which have been approved for listing in China," the relevant person in charge of BeiGene told the People's Daily health client reporter

Among them, including the first local research and development of the global anti-cancer new drug Baiyueze (zebutinib), which has been approved

Bai Zean (tirelizumab), has been approved in China for 9 indications, of which 5 are included in the national medical insurance directory, which is currently the local anti-PD-1 antibody with the largest number of approved indications and the largest number of medical insurance indications

Anjavir (desulumab), the first and currently the only FRANKL inhibitor approved in China for the prevention of bone metastases from solid tumors and bone-related events caused by multiple myeloma, conditionally approved in China for the treatment of adults with non-surgical resection or surgical resection of adults and patients with osteomangioma with developing bone maturation that may lead to severe dysfunction, as well as bone-related event prevention

Bellito (berintoomolumab), the world's first and only approved bispecific antibody drug targeting CD3 and CD19, the first conditionally approved immunotherapy for adult relapsed refractory precursor B-cell acute lymphoblastic leukemia in China, and the first approved immunotherapy program

KaiserBay (β of datuximab), China's first GD2 monoclonal antibody immunotherapy drug

Zhifei Bio: The recombinant novel coronavirus protein vaccine has provided protection for 100 million people

"The recombinant novel coronavirus protein vaccine independently developed by Zhifei Bio (ZhikeWeide) was approved for emergency use in March 2021, and was conditionally listed by the State Food and Drug Administration in 2022, which has provided protection for more than 100 million people around the world", at the scene of the service trade fair, the relevant person in charge of Zhifei Bio introduced

Jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Anhui Zhifei Longkema Biopharmaceutical Co.

The results of the phase III clinical trial of the recombinant new coronavirus published by gao fu team, an academician of the Chinese Academy of Sciences, in the international top medical academic journal "New England Journal of Medicine", show that the new crown vaccine ZF2001 (Zhikeweide) has good safety and efficacy

At present, Zhifei recombinant COVID-19 protein vaccine is the first approved recombinant new coronavirus protein vaccine, which has achieved supply

The relevant person in charge of Zhifei Biology told reporters that in the past two years, we have listed three products: First, the recombinant new crown vaccine Zhikeweide, Zhikeweide has good safety, high immunogenicity, good protection effect, and is the first recombinant subunit new coronavirus vaccine approved for registration and listing in the world and the first recombinant subunit new crown vaccine approved for conditional listing in China; It is currently the only domestic COVID-19 vaccine that publishes three phases of clinical data in top medical journals, with a protective efficacy of more than 80% in 1.

Lizhu Pharmaceutical Group: The first generic drug in China for assisted reproduction appeared at the Service Trade Fair

On September 1, at the scene of the service trade fair "Health and Industrial Technology Integration Innovation Zone", the People's Daily health client reporter saw that Lizhu Pharmaceutical Group mainly displayed a Product of Lidebao, which was the first listed product

The relevant person in charge of Lizhu Pharmaceutical Group told the People's Daily health client reporter that Lidebao is the first domestic imitation of the biosimilar drug of Merck Shelano's drug Aize, which was approved for listing in China in April 2021 and belongs to the assisted reproductive drugs

In addition, Lizhu Pharmaceutical Group and the Institute of Biophysics of the Chinese Academy of Sciences jointly developed an innovative recombinant novel coronavirus fusion protein vaccine with independent intellectual property rights, which belongs to the recombinant protein vaccine route among the five technical routes of the national new crown vaccine

Phase I and Phase II clinical data were published in Emerge Microbes & Infections and the Chinese Medical Journal (English edition) in July 2021, respectively, and data from the sequential Phase III clinical study were published

Hanhui Pharmaceutical: The only Class 1 innovative drug approved in the cardiovascular field in recent years has been included in medical insurance

In the exhibition area of Hanhui Pharmaceutical, the first cholesterol absorption inhibitor with independent intellectual property rights in China was displayed
- Saismei (HaiboMai cloth).
Saismei is also the only Class 1 innovative drug approved by China in the cardiovascular field in recent years, and it is also a major scientific and technological project
of the national "Twelfth Five-Year Plan" and "major new drug creation".

The 1356 people enrolled in the Phase III clinical trial study were all Patients with Hyperlipidemia in China, fully considering the needs of Chinese patients for
lipid therapy.
The study data shows that the peak can be reached within 0.
5-12 hours after taking Sesme, allowing patients to benefit
more quickly under the same time of medication.
It can effectively reduce the burden on the liver, reduce drug accumulation, and make safety better
.

Saisme has been successfully included in the 2021 National Health Insurance Directory
.
Indications are adjunctive therapies other than dietary control and can be used alone or in combination with HMG-CoA reductase inhibitors (statins) for the treatment of primary (heterozygous familial or non-familial) hypercholesterolemia
.

Hanhui Pharmaceutical is a wholly-owned subsidiary of Haizheng Pharmaceutical and currently supplies more than 80 products in the Chinese market, including many of the world's leading original products
.